Comparative Pharmacology
Head-to-head clinical analysis: DIFICID versus PROLOPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIFICID versus PROLOPRIM.
DIFICID vs PROLOPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
Inhibits bacterial dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA, RNA, and protein synthesis.
200 mg (tablet) orally twice daily for 10 days.
100 mg orally twice daily or 200 mg orally once daily.
None Documented
None Documented
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
Terminal elimination half-life is 8-10 hours in normal renal function; prolonged (>20 hours) in significant renal impairment.
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Primarily renal (80-90% as unchanged drug); less than 5% as metabolites; fecal excretion negligible.
Category C
Category C
Antibiotic
Antibiotic